
  
    
      
        Background_NNP
        The_DT results_NNS of_IN cell_NN culture_NN and_CC animal_NN studies_NNS have_VBP
        shown_VBN that_DT omega_NN 3_CD polyunsaturated_JJ fatty_NN acids_NNS (_( n-_NN 3_CD PUFAs_NNP )_)
        selectively_RB killed_VBN cancer_NN cells_NNS 
        in_IN vitro_NN [_NN 1_CD ]_NN ._. Furthermore_RB ,_, n-_NN 3_CD
        PUFAs_NNP incorporated_VBD into_IN animal_NN diets_NNS have_VBP reduced_VBN tumor_NN
        growth_NN rates_NNS 
        in_IN vivo_NN [_NN 2_CD 3_CD 4_CD ]_NN ._. The_DT prevailing_VBG
        hypothesis_NNS for_IN the_DT reduction_NN in_IN tumor_NN cell_NN growth_NN ,_, 
        in_IN vitro_NN or_CC 
        in_IN vivo_NN ,_, by_IN supplementing_VBG the_DT diet_NN
        with_IN high_JJ levels_NNS of_IN n-_NN 3_CD PUFAs_NNP has_VBZ been_VBN that_IN the_DT
        incorporation_NN of_IN n-_NN 3_CD PUFAs_NNP into_IN cell_NN membranes_NNS of_IN the_DT tumor_NN
        cells_NNS increased_VBD the_DT susceptibility_NN of_IN the_DT cells_NNS for_IN lipid_NN
        peroxidation_NN and_CC that_IN the_DT products_NNS of_IN lipid_NN peroxidation_NN
        subsequently_RB accumulated_VBN to_TO cytostatic_JJ or_CC cytotoxic_JJ levels_NNS
        [_NN 2_CD 5_CD 6_CD 7_CD ]_NN ._. It_PRP has_VBZ also_RB been_VBN reported_VBN that_IN supplementing_VBG
        the_DT diet_NN of_IN cancer_NN xenograft_NN bearing_NN mice_NNS with_IN n-_NN 3_CD PUFAs_NNP
        could_MD increase_VB the_DT efficacy_NN of_IN edelfosine_NN [_NN 8_CD ]_NN ,_,
        doxorubicin_NN [_NN 9_CD ]_NN ,_, mitomycin_NN [_NN 10_CD ]_NN ,_, cyclophosphomide_NN and_CC
        5_CD -_: fluorouracil_NN [_NN 11_CD ]_NN or_CC irinotecan_NN [_NN 12_CD ]_NN against_IN the_DT
        tumor_NN ._. Since_IN causing_VBG oxidative_JJ damage_NN is_VBZ one_CD of_IN the_DT
        mechanisms_NNS of_IN action_NN of_IN many_JJ of_IN these_DT drugs_NNS [_NN 13_CD ]_NN ,_, the_DT
        increased_VBN efficacy_NN of_IN the_DT drug_NN has_VBZ been_VBN attributed_VBN to_TO
        increasing_VBG the_DT susceptibility_NN of_IN tumor_NN cell_NN membranes_NNS to_TO
        lipid_NN peroxidation_NN ._.
        However_RB ,_, the_DT results_NNS of_IN one_CD of_IN our_PRP$ early_JJ studies_NNS
        indicated_VBD that_IN some_DT factor_NN in_IN addition_NN to_TO lipid_NN
        peroxidation_NN was_VBD involved_VBN in_IN the_DT reduction_NN in_IN xenograft_NN
        growth_NN in_IN fish_NN oil_NN fed_VBD mice_NNS [_NN 8_CD ]_NN ._. A_DT clue_NN as_IN to_TO this_DT
        factor_NN (_( s_VBZ )_) was_VBD found_VBN in_IN the_DT report_NN by_IN Vankatraman_NNP et_CC al_NN ._.
        that_DT antioxidant_NN enzyme_NN activity_NN in_IN the_DT liver_NN was_VBD altered_VBN
        following_VBG long_JJ term_NN consumption_NN of_IN n-_NN 3_CD PUFAs_NNP [_NN 14_CD ]_NN ._. We_PRP
        reasoned_VBD that_DT alteration_NN of_IN antioxidant_NN enzyme_NN activity_NN in_IN
        the_DT tumor_NN by_IN consumption_NN of_IN n-_NN 3_CD PUFAs_NNP prior_RB to_TO chemotherapy_NN
        treatment_NN could_MD increase_VB oxidative_JJ stress_NN within_IN the_DT tumor_NN ,_,
        perhaps_RB resulting_VBG an_DT enhanced_JJ sensitivity_NN to_TO oxidative_JJ
        stress_NN induced_VBN by_IN doxorubicin_NN (_( DOX_NNP )_) ._.
        In_IN this_DT study_NN ,_, we_PRP wanted_VBD to_TO test_VB the_DT hypothesis_NNS that_IN
        there_EX are_VBP changes_NNS in_IN the_DT breast_NN cancer_NN xenografts_NNS of_IN FOC_NNP
        fed_VBD mice_NNS that_WDT sensitize_VB the_DT tumor_NN to_TO oxidative_JJ stress_NN ._.
        MDA-MB_NNP 231_CD human_JJ breast_NN cancer_NN bearing_VBG athymic_JJ mice_NNS were_VBD
        fed_VBN fish_NN oil_NN concentrate_NN (_( FOC_NNP )_) or_CC control_NN diets_NNS ,_, with_IN and_CC
        without_IN supplemental_JJ vitamin_NN E_NNP and_CC were_VBD euthanized_JJ both_DT
        before_IN and_CC after_IN DOX_NNP treatment_NN to_TO test_VB this_DT hypothesis_NNS ._. DOX_NNP
        was_VBD used_VBN to_TO induce_VB oxidative_JJ stress_NN ,_, supplemental_JJ vitamin_NN E_NNP
        was_VBD used_VBN to_TO quench_NN oxidative_JJ stress_NN ._. An_DT important_JJ aspect_NN of_IN
        the_DT present_JJ study_NN was_VBD that_IN the_DT n-_NN 3_CD PUFAs_NNP dietary_JJ supplement_NN
        be_VB fed_VBN to_TO mice_NNS at_IN a_DT level_NN that_IN humans_NNS could_MD readily_RB
        consume_VB ._. This_DT level_NN was_VBD based_VBN on_IN calculation_NN of_IN calories_NNS
        contributed_VBN by_IN the_DT oil_NN as_IN a_DT fraction_NN of_IN the_DT total_JJ caloric_JJ
        content_NN of_IN the_DT diet_NN ._. A_DT product_NN containing_VBG more_JJR than_IN 65_CD %_NN
        omega_NN 3_CD ethyl_NN esters_NNS was_VBD used_VBN to_TO increase_VB the_DT amount_NN of_IN
        long_JJ chain_NN n-_NN 3_CD PUFAs_NNP contained_VBD in_IN a_DT small_JJ quantity_NN of_IN the_DT
        n-_NN 3_CD PUFAs_NNP supplement_NN ._. A_DT high_JJ amount_NN of_IN α-tocopherol_JJ ,_,
        (_( vitamin_NN E_NNP ,_, 2000_CD IU_NNP /_NN kg_NN diet_NN )_) was_VBD added_VBN to_TO the_DT diet_NN of_IN some_DT
        mice_NNS to_TO suppress_VB lipid_NN peroxidation_NN in_IN tissues_NNS ._.
      
      
        Results_NNS
        
          Fatty_NNP acid_NN composition_NN
          The_DT fatty_NN acid_NN compositions_NNS of_IN the_DT microsomal_NN and_CC
          mitochondrial_NN membrane_NN fractions_NNS of_IN liver_NN ,_, colon_NN and_CC
          MDA-MB_NNP 231_CD human_JJ breast_NN tumor_NN were_VBD analyzed_VBN by_IN gas_NN
          chromatography_NN ._. The_DT individual_JJ percent_NN compositions_NNS for_IN
          α-linolenic_JJ ,_, eicosapentaenoic_JJ and_CC docosahexaenoic_JJ acids_NNS
          were_VBD summed_VBD to_TO estimate_VB the_DT fraction_NN of_IN n-_NN 3_CD fatty_NN acids_NNS ._.
          The_DT individual_JJ percent_NN compositions_NNS for_IN linoleic_JJ and_CC
          arachidonic_JJ acids_NNS were_VBD summed_VBD to_TO estimate_VB the_DT fraction_NN of_IN
          n-_NN 6_CD fatty_NN acids_NNS ._. The_DT ratios_NNS of_IN the_DT n-_NN 3_CD to_TO n-_NN 6_CD fatty_NN acids_NNS
          in_IN each_DT tissue_NN and_CC subcellular_NN fraction_NN were_VBD subjected_VBN to_TO
          statistical_JJ analyses_NNS ._. A_DT two_CD way_NN ANOVA_NNP revealed_VBD that_IN the_DT
          n-_NN 3_CD to_TO n-_NN 6_CD ratio_NN (_( Table_NNP 1_LS )_) was_VBD significantly_RB higher_JJR in_IN
          mice_NNS that_WDT consumed_VBD FOC_NNP than_IN in_IN mice_NNS that_WDT consumed_VBD corn_NN
          oil_NN (_( CO_NNP )_) indicating_VBG that_DT n-_NN 3_CD fatty_NN acids_NNS were_VBD
          incorporated_VBN in_IN cellular_JJ membranes_NNS when_WRB FOC_NNP was_VBD provided_VBN
          in_IN the_DT diet_NN of_IN the_DT diet_NN ._. Supplemental_NNP Vitamin_NNP E_NNP in_IN the_DT
          diet_NN did_VBD not_RB effect_VB the_DT ratio_NN of_IN n-_NN 3_CD to_TO n-_NN 6_CD fatty_NN
          acids_NNS ._.
        
        
          Antioxidant_NNP enzyme_NN activity_NN
          To_TO determine_VB the_DT effect_NN of_IN consumption_NN of_IN FOC_NNP on_IN
          endogenous_JJ antioxidant_NN enzyme_NN activity_NN ,_, the_DT activities_NNS of_IN
          superoxide_NN dismutase_NN (_( SOD_NNP )_) ,_, catalase_NN (_( CAT_NNP )_) and_CC
          glutathione_NN peroxidase_NN (_( GPX_NNP )_) were_VBD determined_VBN in_IN the_DT
          liver_NN ,_, colon_NN and_CC tumor_NN of_IN mice_NNS that_WDT had_VBD consumed_VBN the_DT diet_NN
          for_IN two_CD weeks_NNS ._. As_IN summarized_VBD in_IN Table_NNP 2_CD ,_, two_CD way_NN ANOVA_NNP
          revealed_VBD that_IN the_DT activities_NNS of_IN SOD_NNP ,_, CAT_NNP and_CC GPX_NNP were_VBD not_RB
          significantly_RB altered_VBN in_IN the_DT liver_NN or_CC colon_NN due_JJ to_TO the_DT
          consumption_NN of_IN FOC_NNP or_CC of_IN supplemental_JJ Vitamin_NNP E_NNP for_IN two_CD
          weeks_NNS ._. However_RB ,_, GPX_NNP activity_NN was_VBD significantly_RB less_JJR in_IN
          the_DT tumors_NNS of_IN mice_NNS that_WDT consumed_VBD FOC_NNP than_IN in_IN the_DT tumors_NNS
          of_IN mice_NNS that_WDT consumed_VBD CO_NNP and_CC supplemental_JJ Vitamin_NNP E_NNP did_VBD
          not_RB significantly_RB alter_VB GPX_NNP activity_NN ._. Thus_RB ,_, the_DT effect_NN of_IN
          consumption_NN of_IN FOC_NNP on_IN GPX_NNP activity_NN was_VBD different_JJ in_IN the_DT
          tumor_NN than_IN in_IN the_DT normal_JJ host_NN liver_NN or_CC colon_NN ._.
        
        
          Lipid_NNP peroxidation_NN
          
            1_LS )_) liverand_NN colon_NN
            a_DT )_) Lipid_NNP peroxidation_NN was_VBD slightly_RB suppressed_VBN by_IN the_DT
            addition_NN of_IN vitamin_NN E_NNP to_TO either_CC diet_NN ,_, b_SYM )_) DOX_NNP treatment_NN
            did_VBD not_RB significantly_RB increase_VB lipid_NN peroxidation_NN ._.
          
          
            2_LS )_) tumor_NN
            a_DT )_) Supplemental_NN vitamin_NN E_NNP prevented_VBD an_DT FOC_NNP induced_VBD
            increase_NN in_IN basal_NN lipid_NN peroxidation_NN ,_, b_SYM )_) supplemental_JJ
            vitamin_NN E_NNP prevented_VBD the_DT DOX_NNP induced_VBD increase_NN in_IN lipid_NN
            peroxidation_NN in_IN mice_NNS that_WDT consumed_VBD the_DT corn_NN oil_NN diet_NN
            but_CC did_VBD NOT_NNP prevent_VB a_DT DOX_NNP induced_VBD increase_NN in_IN lipid_NN
            peroxidation_NN in_IN mice_NNS that_WDT consumed_VBD the_DT FOC_NNP diet_NN ._.
          
        
        
          Tumor_NNP growth_NN rates_NNS
          Figure_NN 1_CD illustrates_VBZ the_DT mean_JJ growth_NN rates_NNS of_IN the_DT
          tumors_NNS of_IN each_DT dietary_JJ group_NN following_VBG DOX_NNP treatment_NN ._.
          ANOVA_NNP revealed_VBD that_IN the_DT growth_NN rates_NNS of_IN the_DT tumors_NNS of_IN
          both_DT groups_NNS that_WDT consumed_VBD FOC_NNP were_VBD significantly_RB less_JJR
          than_IN the_DT mean_JJ growth_NN rates_NNS of_IN both_DT of_IN the_DT groups_NNS of_IN mice_NNS
          that_WDT consumed_VBD either_DT CO_NNP diet_NN ._.
        
        
          Multiple_NNP regression_NN analyses_NNS
          Values_NNP for_IN the_DT means_NNS of_IN SOD_NNP ,_, CAT_NNP ,_, GPX_NNP activities_NNS and_CC
          TBARS_NNP from_IN the_DT tumors_NNS of_IN groups_NNS of_IN mice_NNS killed_VBN after_IN two_CD
          weeks_NNS on_IN each_DT diet_NN with_IN or_CC without_IN DOX_NNP treatment_NN and_CC the_DT
          mean_JJ tumor_NN growth_NN rate_NN of_IN mice_NNS fed_VBD each_DT diet_NN and_CC treated_VBN
          with_IN DOX_NNP for_IN five_CD weeks_NNS were_VBD entered_VBN into_IN a_DT forward_RB
          multiple_JJ regression_NN analyses_NNS ._. Multiple_NNP regression_NN
          analyses_NNS can_MD address_VB the_DT question_NN :_: What_WP variable_JJ (_( s_VBZ )_)
          present_JJ in_IN the_DT tumor_NN prior_RB to_TO or_CC after_IN DOX_NNP treatment_NN best_JJS
          correlates_NNS with_IN the_DT response_NN of_IN the_DT tumor_NN to_TO DOX_NNP
          treatment_NN ?_. The_DT results_NNS of_IN the_DT analyses_NNS (_( Table_NNP 4_LS )_) revealed_VBD
          that_IN GPX_NNP activity_NN in_IN the_DT tumor_NN prior_RB to_TO DOX_NNP treatment_NN
          explained_VBD 78_CD %_NN of_IN the_DT variation_NN in_IN tumor_NN growth_NN rate_NN (_( the_DT
          correlation_NN coefficient_NN (_( r_LS )_) between_IN GPX_NNP activity_NN in_IN the_DT
          tumor_NN before_IN DOX_NNP treatment_NN and_CC the_DT tumor_NN growth_NN rate_NN
          following_VBG DOX_NNP treatment_NN was_VBD 0_CD ._. 88_CD )_) ._. Increased_VBN TBARS_NNP
          following_VBG DOX_NNP treatment_NN added_VBD an_DT additional_JJ 19_CD %_NN
          explanation_NN for_IN the_DT variation_NN in_IN tumor_NN growth_NN rate_NN ._. Thus_RB ,_,
          97_CD %_NN of_IN the_DT variation_NN in_IN tumor_NN growth_NN rate_NN could_MD be_VB
          explained_VBN by_IN the_DT diet_NN induced_VBN decrease_VB in_IN GPX_NNP activity_NN
          and_CC by_IN increased_VBN lipid_NN peroxidation_NN in_IN the_DT tumor_NN
          following_VBG DOX_NNP treatment_NN ._.
        
        
          Body_NN weight_NN
          The_DT mean_JJ body_NN weight_NN change_NN of_IN each_DT group_NN of_IN tumor_NN
          bearing_NN mice_NNS following_VBG consumption_NN of_IN each_DT diet_NN for_IN two_CD
          weeks_NNS or_CC following_VBG DOX_NNP treatment_NN for_IN five_CD weeks_NNS was_VBD
          determined_VBN ._. Two_CD way_NN ANOVA_NNP (_( Table_NNP 5_LS )_) revealed_VBD that_DT
          addition_NN of_IN Vitamin_NNP E_NNP to_TO the_DT diet_NN did_VBD not_RB significantly_RB
          effect_VB body_NN weight_NN but_CC that_IN mice_NNS that_WDT consumed_VBD FOC_NNP prior_RB
          to_TO DOX_NNP treatment_NN gained_VBD significantly_RB more_JJR weight_NN than_IN
          did_VBD mice_NNS that_WDT consumed_VBD CO_NNP ._. Neither_DT fat_JJ type_NN nor_CC Vitamin_NNP E_NNP
          supplementation_NN significantly_RB altered_VBD the_DT change_NN in_IN body_NN
          weight_NN during_IN five_CD weeks_NNS of_IN DOX_NNP treatment_NN ._.
        
      
      
        Discussion_NNP
        
          Body_NN weight_NN and_CC tumor_NN growth_NN rate_NN
          It_PRP has_VBZ been_VBN reported_VBN that_DT omega_NN 3_CD fatty_NN acids_NNS can_MD
          decrease_VB tumor_NN cachexia_NN [_NN 19_CD 20_CD 21_CD ]_NN ._. It_PRP is_VBZ important_JJ to_TO
          note_VB that_DT tumor_NN bearing_NN mice_NNS that_WDT received_VBD only_RB 3_CD %_NN FOC_NNP in_IN
          their_PRP$ diet_NN gained_VBD more_JJR weight_NN prior_RB to_TO initiation_NN of_IN DOX_NNP
          therapy_NN than_IN mice_NNS that_WDT did_VBD not_RB receive_VB FOC_NNP ._. At_IN the_DT
          initiation_NN of_IN DOX_NNP therapy_NN ,_, the_DT tumors_NNS of_IN FOC_NNP fed_VBD mice_NNS
          were_VBD slightly_RB ,_, (_( but_CC not_RB significantly_RB )_) smaller_JJR than_IN the_DT
          tumors_NNS of_IN the_DT CO_NNP fed_VBD mice_NNS and_CC at_IN the_DT end_NN of_IN the_DT study_NN the_DT
          tumors_NNS of_IN FOC_NNP fed_VBD mice_NNS were_VBD significantly_RB smaller_JJR than_IN
          the_DT tumors_NNS of_IN CO_NNP fed_VBD mice_NNS ,_, thus_RB the_DT higher_JJR weight_NN gain_NN
          has_VBZ to_TO be_VB body_NN weight_NN ,_, not_RB tumor_NN weight_NN ._. The_DT
          significantly_RB higher_JJR body_NN weight_NN gain_NN is_VBZ likely_JJ due_NN to_TO
          reduced_VBN tumor_NN related_VBD cachexia_NN ._.
          CO_NNP and_CC FOC_NNP fed_VBD groups_NNS did_VBD not_RB lose_VB different_JJ amounts_NNS
          of_IN body_NN weight_NN during_IN DOX_NNP treatment_NN ._. This_DT fact_NN and_CC the_DT
          maintenance_NN of_IN antioxidant_NN enzyme_NN production_NN in_IN colon_NN and_CC
          liver_NN are_VBP indications_NNS that_IN the_DT toxicity_NN of_IN DOX_NNP to_TO normal_JJ
          host_NN tissues_NNS was_VBD not_RB increased_VBN by_IN the_DT FOC_NNP diet_NN ._.
          The_DT tumor_NN growth_NN curves_NNS (_( Figure_NN 1_LS )_) illustrate_VBP the_DT
          significant_JJ enhancement_NN of_IN the_DT efficacy_NN of_IN DOX_NNP against_IN
          MDA-MB_NNP 231_CD human_JJ breast_NN cancer_NN xenografts_NNS when_WRB FOC_NNP was_VBD
          incorporated_VBN in_IN the_DT diet_NN ._. The_DT tumor_NN growth_NN rate_NN of_IN mice_NNS
          consuming_NN either_CC FOC_NNP diet_NN was_VBD significantly_RB less_JJR than_IN the_DT
          tumor_NN growth_NN rate_NN of_IN mice_NNS consuming_NN either_CC CO_NNP diet_NN ._. It_PRP is_VBZ
          interesting_JJ that_IN adding_VBG vitamin_NN E_NNP to_TO the_DT CO_NNP diet_NN slightly_RB
          increased_VBD the_DT mean_JJ growth_NN rate_NN of_IN the_DT tumors_NNS ._. Since_IN
          vitamin_NN E_NNP quenches_NNS oxidation_NN and_CC oxidative_JJ damage_NN is_VBZ one_CD
          of_IN the_DT mechanisms_NNS of_IN action_NN of_IN DOX_NNP [_NN 13_CD ]_NN ,_, it_PRP would_MD be_VB
          expected_VBN that_DT addition_NN of_IN vitamin_NN E_NNP to_TO the_DT diet_NN of_IN mice_NNS
          bearing_NN tumors_NNS with_IN adequate_JJ GPX_NNP activity_NN ,_, might_MD reduce_VB
          the_DT efficacy_NN of_IN DOX_NNP against_IN the_DT tumor_NN ._.
        
      
      
        Conclusions_NNP
        These_DT results_NNS indicate_VBP that_DT n-_NN 3_CD PUFAs_NNP in_IN the_DT diet_NN are_VBP
        incorporated_VBN in_IN cell_NN membranes_NNS ,_, increasing_VBG the_DT
        polyunsaturation_NN of_IN the_DT membrane_NN and_CC increasing_VBG the_DT
        susceptibility_NN for_IN lipid_NN peroxidation_NN ._. The_DT inability_NN of_IN
        cancer_NN cells_NNS to_TO maintain_VB the_DT activity_NN of_IN GPX_NNP in_IN the_DT
        presence_NN of_IN a_DT diet_NN containing_VBG n-_NN 3_CD PUFAs_NNP was_VBD related_VBN to_TO
        increased_VB oxidative_JJ damage_NN to_TO membrane_NN lipids_NNS and_CC to_TO
        significant_JJ enhancement_NN of_IN the_DT efficacy_NN of_IN DOX_NNP therapy_NN ._.
        Tumor_NNP bearing_NN mice_NNS that_WDT consumed_VBD n-_NN 3_CD PUFAs_NNP gained_VBD more_JJR
        weight_NN prior_RB to_TO DOX_NNP therapy_NN than_IN mice_NNS that_WDT did_VBD not_RB receive_VB
        n-_NN 3_CD PUFAs_NNP indicating_VBG that_DT tumor_NN induced_VBD cachexia_NN was_VBD
        reduced_VBN ._. Clinical_NNP trials_NNS are_VBP needed_VBN to_TO test_VB the_DT use_NN of_IN this_DT
        non-toxic_JJ supplement_NN as_IN an_DT adjuvant_NN for_IN patients_NNS undergoing_VBG
        DOX_NNP chemotherapy_NN ._.
      
      
        Methods_NNP and_CC Materials_NNPS
        
          Preparation_NNP of_IN cells_NNS
          Cultured_NNP MDA-MB_NNP 231_CD cells_NNS (_( American_NNP Type_NNP Culture_NNP
          Collection_NNP ,_, Rockville_NNP ,_, MD_NNP )_) were_VBD harvested_VBN ,_, rinsed_JJ then_RB
          suspended_VBN in_IN serum-free_JJ M_NNP 3_CD D_NNP base_NN culture_NN medium_NN (_( INCELL_NNP
          Corporation_NNP ,_, LLC_NNP ,_, San_NNP Antonio_NNP ,_, TX_NNP )_) ._. Cells_NNP in_IN suspension_NN
          were_VBD counted_VBN using_VBG a_DT hemocytometer_NN and_CC the_DT cell_NN count_NN was_VBD
          adjusted_VBN to_TO 20_CD ×_NN 10_CD 6_CD /_NN ml_NN ._. The_DT suspension_NN was_VBD kept_VBN well_RB
          mixed_JJ during_IN the_DT time_NN of_IN injection_NN ._. MDA-MB_NNP 231_CD cells_NNS (_( 1_CD ×_NN
          10_CD 6_CD cells_NNS in_IN 0_CD ._. 05_CD ml_NN of_IN serum_NN free_JJ media_NNS )_) were_VBD injected_VBN
          sc_NN between_IN the_DT scapulae_NN of_IN each_DT mouse_NN ._.
        
        
          Dietary_NNP fatty_NN acids_NNS
          Corn_NN oil_NN (_( CO_NNP )_) contains_VBZ about_IN 50_CD %_NN linoleic_JJ acid_NN ,_, 23_CD %_NN
          oleic_JJ acid_NN ,_, 10_CD %_NN C_NNP 16_CD fatty_NN acids_NNS and_CC <_NN 1_CD %_NN n-_NN 3_CD PUFAs_NNP ._.
          The_DT n-_NN 3_CD ethyl_NN ester_NN concentrate_NN of_IN fish_NN oil_NN (_( FOC_NNP )_)
          containing_VBG >_NN 65_CD %_NN n-_NN 3_CD ethyl_NN esters_NNS ,_, (_( >_NN 33_CD %_NN EPA_NNP ,_, >_NN
          22_CD %_NN DHA_NNP ,_, 10_CD %_NN other_JJ n-_NN 3_CD fatty_NN acids_NNS )_) ,_, was_VBD obtained_VBN from_IN
          the_DT Lipro_NNP AS_NNP ,_, Norway_NNP and_CC was_VBD supplied_VBN antioxidant-free_JJ ._.
          This_DT oil_NN is_VBZ made_VBN in_IN accordance_NN with_IN Good_NNP Manufacturing_NNP
          Practice_NNP and_CC is_VBZ approved_VBN as_IN a_DT food_NN additive_JJ for_IN humans_NNS ._.
          The_DT oil_NN is_VBZ saturated_VBN with_IN nitrogen_NN to_TO prevent_VB oxidation_NN
          during_IN shipping_VBG and_CC storage_NN ._.
        
        
          Animals_NNS and_CC diet_NN
          This_DT experiment_NN was_VBD conducted_VBN at_IN the_DT University_NNP of_IN
          Texas_NNP Health_NNP Science_NNP Center_NNP ._. All_DT animal_NN use_NN and_CC handling_VBG
          was_VBD approved_VBN by_IN the_DT UTHSCSA_NNP Institutional_NNP Animal_NNP Care_NNP and_CC
          Use_NNP Committee_NNP ._. Eighty_NNP female_JJ athymic_JJ nu_NN /_NN nu_NN mice_NNS (_( Harlan_NNP
          Sprague_NNP Dawley_NNP Inc_NNP ._. Madison_NNP ,_, WI_NNP )_) ,_, 3_CD months_NNS old_JJ received_JJ
          tumor_NN cells_NNS ._. The_DT mice_NNS were_VBD housed_VBN under_IN aseptic_JJ
          conditions_NNS in_IN a_DT temperature_NN (_( 24_CD °_NN C_NNP )_) and_CC light-controlled_JJ
          (_( 12_CD h_NN /_NN day_NN )_) room_NN ._.
          The_DT tumor_NN cell_NN bearing_NN mice_NNS were_VBD fed_VBN the_DT AIN-_NNP 76_CD
          semipurified_JJ diet_NN from_IN receipt_NN until_IN three_CD weeks_NNS after_IN
          injection_NN of_IN cells_NNS to_TO allow_VB the_DT tumor_NN to_TO become_VB
          established_VBN ._. Nude_NNP mice_NNS bearing_NN growing_VBG MDA-MB-_NNP 231_CD human_JJ
          breast_NN carcinoma_NN xenografts_NNS were_VBD then_RB divided_VBN into_IN four_CD
          dietary_JJ groups_NNS (_( 20_CD mice_NNS per_IN group_NN )_) such_JJ that_IN the_DT mean_JJ
          tumor_NN size_NN was_VBD not_RB different_JJ between_IN groups_NNS ._. One_CD group_NN
          received_VBD the_DT standard_JJ AIN-_NNP 76_CD diet_NN containing_VBG 5_CD %_NN CO_NNP (_( the_DT
          CO_NNP diet_NN )_) ,_, one_CD group_NN received_VBD the_DT 5_CD %_NN CO_NNP diet_NN supplemented_JJ
          with_IN 2000_CD IU_NNP /_NN kg_NN Vitamin_NNP E_NNP (_( the_DT CO_NNP +_NN E_NNP diet_NN )_) ,_, one_CD group_NN ,_,
          received_VBD the_DT AIN-_NNP 76_CD diet_NN modified_VBN to_TO contain_VB 3_CD %_NN FOC_NNP and_CC
          2_CD %_NN CO_NNP (_( the_DT FOC_NNP diet_NN )_) and_CC the_DT final_JJ group_NN received_VBD the_DT 3_CD %_NN
          FOC_NNP and_CC 2_CD %_NN CO_NNP supplemented_JJ with_IN 2000_CD IU_NNP /_NN kg_NN Vitamin_NNP E_NNP (_( the_DT
          FOC_NNP +_NN E_NNP diet_NN )_) ._. Supplemental_NN vitamin_NN E_NNP was_VBD added_VBN to_TO quench_NN 
          in_IN vivo_NN lipid_NN peroxidation_NN due_JJ to_TO
          the_DT diet_NN ._. The_DT diet_NN composition_NN is_VBZ given_VBN in_IN Table_NNP 6_CD ._. Diets_NNP
          were_VBD prepared_VBN weekly_JJ ,_, daily_JJ portions_NNS were_VBD individually_RB
          packaged_VBN and_CC stored_VBN at_IN -_: 20_CD °_NN C_NNP in_IN sealed_VBN containers_NNS with_IN
          nitrogen_NN gas_NN atmosphere_NN to_TO prevent_VB lipid_NN peroxidation_NN ._.
          Mice_NNS were_VBD fed_VBN fresh_JJ food_NN each_DT day_NN and_CC food_NN remaining_VBG in_IN
          the_DT cage_NN was_VBD discarded_VBN ._.
        
        
          Tumor_NNP and_CC body_NN weight_NN measurements_NNS
          Lengths_NNP and_CC widths_NNS of_IN tumors_NNS and_CC body_NN weights_NNS were_VBD
          measured_VBN three_CD times_NNS weekly_JJ ._. Tumor_NNP sizes_NNS were_VBD calculated_VBN
          using_VBG the_DT formula_NN for_IN the_DT volume_NN of_IN a_DT prolate_NN spheroid_NN :_: V_NNP
          =_SYM 4_CD /_NN 3_CD *_NN 3_CD ._. 14_CD *_NN L_NNP /_NN 2_CD *_NN W_NNP /_NN 2_CD *_NN D_NNP /_NN 2_CD ._. The_DT width_NN measurement_NN was_VBD
          used_VBN as_IN the_DT depth_NN of_IN the_DT tumor_NN ._. The_DT body_NN weight_NN change_NN
          before_IN DOX_NNP treatment_NN was_VBD determined_VBN by_IN subtracting_VBG the_DT
          mouse_NN body_NN weight_NN on_IN the_DT day_NN of_IN the_DT diet_NN change_NN from_IN the_DT
          body_NN weight_NN on_IN the_DT day_NN of_IN the_DT first_JJ DOX_NNP treatment_NN ,_, thus_RB
          this_DT represents_VBZ body_NN weight_NN change_NN due_JJ to_TO effects_NNS of_IN the_DT
          growing_VBG tumor_NN and_CC of_IN the_DT diet_NN ._. The_DT body_NN weight_NN change_NN
          after_IN DOX_NNP treatment_NN was_VBD determined_VBN by_IN subtracting_VBG the_DT
          mouse_NN body_NN weight_NN on_IN the_DT day_NN of_IN the_DT first_JJ DOX_NNP injection_NN
          from_IN the_DT mouse_NN body_NN weight_NN on_IN the_DT day_NN of_IN killing_VBG and_CC
          represents_VBZ body_NN weight_NN change_NN due_JJ to_TO diet_NN ,_, to_TO the_DT growing_VBG
          tumor_NN and_CC to_TO DOX_NNP therapy_NN ._.
        
        
          Doxorubicin_NNP therapy_NN
          After_IN two_CD weeks_NNS of_IN consumption_NN of_IN the_DT diets_NNS ,_, five_CD
          tumor_NN bearing_NN mice_NNS from_IN each_DT dietary_JJ group_NN were_VBD killed_VBN
          for_IN assay_NN of_IN the_DT effects_NNS of_IN the_DT diet_NN on_IN the_DT tumor_NN and_CC
          normal_JJ tissues_NNS of_IN the_DT mice_NNS ._. DOX_NNP therapy_NN (_( 5_CD mg_NN /_NN kg_NN body_NN
          weight_NN each_DT 4_CD days_NNS ,_, i_NNP ._. v_NN ._. in_IN a_DT lateral_NN tail_NN vein_NN )_) was_VBD
          initiated_VBN on_IN the_DT remaining_VBG mice_NNS of_IN each_DT group_NN ._. Five_CD tumor_NN
          bearing_NN mice_NNS from_IN each_DT group_NN were_VBD killed_VBN 24_CD h_NN after_IN one_CD
          dose_NN of_IN DOX_NNP for_IN determination_NN of_IN the_DT acute_JJ effects_NNS of_IN DOX_NNP
          on_IN the_DT sensitized_JJ tumors_NNS and_CC normal_JJ tissues_NNS ._. After_IN two_CD
          weeks_NNS of_IN DOX_NNP treatment_NN ,_, mice_NNS were_VBD losing_VBG excess_JJ weight_NN at_IN
          the_DT given_VBN schedule_NN of_IN DOX_NNP treatment_NN so_IN the_DT spacing_VBG of_IN
          injections_NNS was_VBD increased_VBN to_TO each_DT seven_CD days_NNS for_IN the_DT next_JJ
          three_CD weeks_NNS and_CC mouse_NN weight_NN stabilized_VBN ._. The_DT remainder_NN of_IN
          the_DT mice_NNS (_( 10_CD per_IN diet_NN group_NN )_) received_VBD DOX_NNP treatment_NN for_IN a_DT
          total_NN of_IN five_CD weeks_NNS to_TO allow_VB time_NN to_TO generate_VB tumor_NN
          growth_NN curves_NNS and_CC to_TO determine_VB the_DT long_JJ term_NN effects_NNS of_IN
          FOC_NNP consumption_NN and_CC /_NN or_CC DOX_NNP treatment_NN ._. Thus_RB if_IN day_NN 0_CD was_VBD
          the_DT day_NN of_IN the_DT first_JJ injection_NN ,_, mice_NNS received_VBD DOX_NNP
          injections_NNS on_IN days_NNS 0_CD ,_, 4_CD ,_, 8_CD ,_, 12_CD ,_, 19_CD ,_, 26_CD ,_, and_CC 33_CD and_CC were_VBD
          sacrificed_JJ on_IN day_NN 1_CD or_CC on_IN day_NN 34_CD ._.
        
        
          Necropsy_NNP and_CC tissue_NN processing_NN
          Mice_NNS were_VBD deeply_RB anesthetized_JJ using_VBG a_DT ketamine_NN /_NN rompun_NN
          solution_NN prepared_VBN by_IN the_DT UTHSCSA_NNP veterinarian_NN ._. The_DT tumor_NN ,_,
          liver_NN and_CC large_JJ intestines_NNS were_VBD removed_VBN at_IN necropsy_NN ._.
          Portions_NNP of_IN each_DT tissue_NN were_VBD placed_VBN individually_RB in_IN a_DT
          labeled_VBN vial_NN and_CC flash_VBP frozen_VBN in_IN liquid_JJ nitrogen_NN ._. At_IN a_DT
          later_JJ date_NN ,_, frozen_VBN livers_NNS ,_, colon_NN or_CC tumor_NN were_VBD thawed_JJ and_CC
          homogenized_JJ individually_RB at_IN 4_CD °_NN C_NNP in_IN 280_CD mM_NN mannitol_NN with_IN
          10_CD mM_NN HEPES_NNP buffer_NN with_IN 0_CD ._. 01_CD %_NN BHT_NNP using_VBG a_DT Polytron_NNP
          homogenizer_NN ._. The_DT homogenate_NN was_VBD divided_VBN into_IN aliquots_NNS and_CC
          frozen_VBN at_IN -_: 70_CD °_NN C_NNP until_IN subsequent_JJ analyses_NNS ._.
        
        
          Products_NNPS of_IN lipid_NN peroxidation_NN in_IN tumor_NN ,_, liver_NN ,_, and_CC
          colon_NN
          The_DT total_JJ protein_NN content_NN of_IN an_DT aliquot_NN of_IN each_DT tissue_NN
          homogenate_NN was_VBD analyzed_VBN by_IN the_DT method_NN of_IN Bradford_NNP [_NN 22_CD ]_NN
          using_VBG the_DT Bio-_NNP Rad_NNP protein_NN assay_NN (_( micro-method_JJ )_) ._. The_DT
          thiobarbituric_JJ acid_NN reactive_JJ substances_NNS (_( TBARS_NNP )_) assay_NN was_VBD
          used_VBN to_TO estimate_VB lipid_NN peroxidation_NN in_IN the_DT homogenate_NN ._.
          Malondialdehyde_NNP and_CC other_JJ products_NNS of_IN lipid_NN peroxidation_NN
          can_MD be_VB estimated_VBN spectrophotometrically_RB at_IN 535_CD nm_NN after_IN
          reaction_NN with_IN thiobarbituric_JJ acid_NN to_TO obtain_VB an_DT index_NN for_IN
          lipid_NN peroxidation_NN [_NN 23_CD ]_NN ._. The_DT absorbance_NN values_NNS
          obtained_VBN were_VBD compared_VBN against_IN a_DT standard_JJ curve_NN of_IN known_VBN
          concentrations_NNS of_IN malondialdehyde_NN and_CC normalized_JJ to_TO the_DT
          protein_NN content_NN of_IN the_DT specimen_NN ._. The_DT results_NNS were_VBD
          reported_VBN as_IN nmol_NN of_IN TBARS_NNP per_IN mg_NN of_IN protein_NN ._.
        
        
          Gas_NN chromatography_NN (_( GC_NNP )_)
          The_DT incorporation_NN of_IN fatty_NN acids_NNS into_IN the_DT mitochondria_NN
          and_CC microsomes_NNS of_IN colon_NN ,_, liver_NN and_CC tumor_NN was_VBD determined_VBN
          in_IN mice_NNS which_WDT consumed_VBD each_DT diet_NN ._. An_DT aliquot_NN of_IN each_DT
          whole_JJ tissue_NN homogenate_NN was_VBD fractioned_JJ into_IN mitochondrial_NN
          and_CC microsomal_NN fractions_NNS by_IN successive_JJ centrifugation_NN
          [_NN 600_CD ×_NN g_SYM for_IN 10_CD min_NN (_( remove_VB large_JJ debris_NN )_) ,_, 15_CD ,_, 000_CD ×_NN g_SYM for_IN
          5_CD min_NN (_( mitochondrial_NN fraction_NN )_) ,_, then_RB 100_CD ,_, 000_CD ×_NN g_SYM for_IN 1_CD h_NN
          (_( microsomal_NN fraction_NN )_) ]_NN for_IN assay_NN of_IN lipid_NN composition_NN ._.
          Chloroform_NNP :_: methanol_NN was_VBD used_VBN for_IN lipid_NN extraction_NN of_IN each_DT
          fraction_NN ;_: lipids_NNS were_VBD esterified_JJ in_IN acetyl_NN
          chloride-methanol_JJ as_IN described_VBN [_NN 24_CD ]_NN ._. Gas_NNP
          chromatography_NN was_VBD done_VBN using_VBG a_DT Hewlett_NNP Packard_NNP 5890_CD
          Series_NNP 11_CD Gas_NNP Chromatograph_NNP (_( Palo_NNP Alto_NNP ,_, CA_NNP )_) and_CC
          conditions_NNS of_IN :_: oven_NN @_IN 170_CD °_NN C_NNP initial_NN ,_, 5_CD °_NN /_NN min_NN gradient_NN to_TO
          220_CD °_NN C_NNP final_JJ temperature_NN ,_, injector_NN temperature_NN @_IN 225_CD °_NN C_NNP ,_,
          flame-ionization_JJ detector_NN @_IN 250_CD °_NN C_NNP ,_, helium_NN carrier_NN gas_NN @_IN
          400_CD Kpa_NNP ._. Fatty_NNP acid_NN methyl_NN ester_NN standards_NNS (_( Nu-_NNP Chek-_NNP Prep_NNP ,_,
          Elysian_NNP ,_, MN_NNP )_) were_VBD used_VBN for_IN peak_NN identification_NN ._. The_DT fatty_NN
          acid_NN methyl_NN esters_NNS were_VBD reported_VBN as_IN the_DT percent_NN of_IN the_DT
          total_JJ methylated_JJ fatty_NN acids_NNS (_( area_NN under_IN the_DT curve_NN )_) ._.
        
        
          Enzyme_NNP assays_NNS
          Catalase_NNP (_( CAT_NNP )_) activity_NN in_IN the_DT tissue_NN homogenates_NNS was_VBD
          assayed_JJ using_VBG a_DT microplate_NN adaptation_NN of_IN the_DT method_NN of_IN
          Aebi_NNP [_NN 25_CD ]_NN ._. In_IN this_DT method_NN ,_, the_DT decomposition_NN of_IN H_NNP 
          2_CD O_NNP 
          2_CD due_JJ to_TO CAT_NNP activity_NN was_VBD assayed_JJ by_IN
          the_DT decrease_NN in_IN the_DT absorbance_NN of_IN H_NNP 
          2_CD O_NNP 
          2_CD at_IN 240_CD nm_NN ._.
          Superoxide_NNP dismutase_NN (_( SOD_NNP )_) activity_NN of_IN tissue_NN
          homogenates_NNS was_VBD determined_VBN using_VBG a_DT microplate_NN adaptation_NN
          of_IN the_DT ferricytochrome_NN C_NNP reduction_NN assay_NN of_IN Flohé_NNP and_CC
          Ötting_VBG [_NN 26_CD ]_NN ._. In_IN this_DT method_NN ,_, the_DT reduction_NN of_IN
          cytochrome_NN C_NNP by_IN superoxide_NN radicals_NNS is_VBZ monitored_VBN at_IN 550_CD
          nm_NN utilizing_VBG the_DT xanthine-xanthine_JJ oxidase_NN system_NN as_IN the_DT
          source_NN for_IN superoxide_NN ._.
          Glutathione_NNP peroxidase_NN (_( GPX_NNP )_) activity_NN of_IN tissue_NN
          homogenates_NNS was_VBD determined_VBN using_VBG a_DT microplate_NN adaptation_NN
          of_IN the_DT glutathione_NN peroxidase_NN assay_NN of_IN Paglia_NNP and_CC
          Valentine_NNP [_NN 27_CD ]_NN ._. This_DT method_NN follows_VBZ the_DT decrease_NN in_IN
          absorbance_NN at_IN 340_CD nm_NN as_IN NADPH_NNP is_VBZ converted_VBN to_TO NADP_NNP ._.
        
        
          Statistical_NNP analyses_NNS
          SAS_NNP computer_NN software_NN was_VBD used_VBN for_IN statistical_JJ
          analyses_NNS ._. Tests_NNP for_IN normality_NN (_( basic_JJ statistics_NNS )_) were_VBD
          used_VBN on_IN each_DT data_NNS set_VBN ._. Two-way_NNP and_CC one-way_JJ analyses_NNS of_IN
          variance_NN (_( ANOVA_NNP )_) followed_VBN by_IN Student-_NNP Newman-_NNP Keuls_NNP (_( SNK_NNP )_)
          multiple_JJ range_NN tests_NNS ,_, as_IN appropriate_JJ ,_, were_VBD used_VBN to_TO
          determine_VB statistically_RB significant_JJ (_( p_NN <_NN 0_CD ._. 05_CD )_)
          differences_NNS in_IN measured_VBN parameters_NNS due_JJ to_TO the_DT diet_NN or_CC to_TO
          the_DT chemotherapy_NN ._. PRISM_NNP ™_NN (_( GraphPad_NNP Software_NNP ,_, San_NNP Diego_NNP ,_,
          CA_NNP )_) was_VBD used_VBN to_TO generate_VB an_DT ANOVA_NNP to_TO test_VB for_IN differences_NNS
          between_IN linear_JJ regression_NN curves_NNS of_IN tumor_NN growth_NN ._.
          Multiple_NNP linear_JJ regression_NN analysis_NN with_IN forward_RB
          selection_NN was_VBD used_VBN to_TO test_VB for_IN correlations_NNS in_IN the_DT data_NNS
          between_IN the_DT independent_JJ variables_NNS :_: SOD_NNP ,_, CAT_NNP and_CC GPX_NNP
          activity_NN in_IN the_DT tumor_NN prior_RB to_TO DOX_NNP therapy_NN ,_, and_CC TBARS_NNP
          prior_RB to_TO or_CC after_IN DOX_NNP therapy_NN and_CC the_DT dependent_JJ variable_NN ,_,
          the_DT tumor_NN growth_NN rate_NN following_VBG DOX_NNP treatment_NN ._.
        
      
    
  
